X4 Pharmaceuticals Inc
Follow $XFOR
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $XFOR by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is XFOR moving today?
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
XFOR overview
Related filings and maps
Congress activity in XFOR
No receipt-qualified Congressional disclosure is present for XFOR in the cached public ledger.
XFOR contract awards, year to date.
Public federal awards linked to this ticker.
XFOR lobbying filings, year to date.
Registered lobbying filings matched to X4 Pharmaceuticals Inc.